Touchstone
Last syncNov 1, 2026, 6:55 PM ET

HRMY

Harmony Biosciences Holdings, Inc. Health Care Pharmaceutical Preparations Russell 3000
$38.76Close $2.2BMarket cap $26.54 – $42.8652-week range Nov 4, 2026Next report · before the open

Highlights

Strengths

  • Earnings growing EPS +89% year on year, faster than the quarter before (+118 pts)

Cautions

  • Trend not confirmed 7 of 8 conditions · under the 50-day
  • Results soon Nov 4, 2026, in 3 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 4, 2026
Off 12-month high 10%
1wk up 7.3% price change
1mo down 1.3% price change
12-month return up 34% market up 11% · its own up 21%
F-score 5 / 9 Mixed
Altman Z 5.36 Low risk
P/E 14.1× price / earnings
PEG 1.80 P/E / EPS growth
P/B 2.6× price / book
Earnings yield up 12.8% EBIT / enterprise value
Cheaper than 84% of the market · markedly cheap
Revenue growth up 22% year on year
EPS growth up 89% latest quarter · +118 pts
Sales growth up 30% latest quarter · +14 pts
ROE up 21% return on equity
Free cash margin up 40% $347.9M FCF
D/E 0.17 long-term debt / equity
Net debt / EBITDA -2.9× net cash
Interest cover 14.2×EBIT / interest
Piotroski tests
  • profitability slipped from last year
  • issued more shares
  • gross margin narrowed
  • assets working less efficiently
  • profitable on its assets
  • generating cash from operations
  • profits backed by cash
  • reduced long-term debt
  • short-term liquidity improved

Repair signals

  • Long-term debt down 12% ($0.2B → $0.1B)

Trade setup

ATR% 3.9% $1.51 a day · 2×ATR $35.74
RS 71 / 99 vs the universe
Trend 7 / 8 under the 50-day
Relative volume 0.9× vs 50-day average
Up/down volume 1.20 50 sessions
Implied move — no option chain · report Nov 4, 2026
Trend template · 7 of 8
  • Price above the 50-day average: fails

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged
  • No restatement or impairment
  • Equity positive
  • Interest covered
  • No material dilution
  • Profits tracking cash
  • Margins and revenue not shrinking
Last reported Aug 4, 2026
Results reaction Aug 4, 2026+6% vs market2 sessions after results

Financials

6 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $868.5M +22% on FY2024
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $159.7M FY2021 · $305.4M FY2022 · $437.9M FY2023 · $582.0M FY2024 · $714.7M FY2025 · $868.5M
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $158.7M +9% on FY2024
-$50M $0 $200M FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · -$36.9M FY2021 · $34.6M FY2022 · $181.5M FY2023 · $128.9M FY2024 · $145.5M FY2025 · $158.7M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $347.9M +59% on FY2024
$0 $500M FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · -$3.0M FY2021 · $98.3M FY2022 · $144.3M FY2023 · $219.1M FY2024 · $218.7M FY2025 · $347.9M
Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology
  • Gross 77%
  • Net 18%
  • Free cash 40%
-25% 0% 100% FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Gross 83% · Net -23% · Free cash -2% FY2021 · Gross 82% · Net 11% · Free cash 32% FY2022 · Gross 81% · Net 41% · Free cash 33% FY2023 · Gross 79% · Net 22% · Free cash 38% FY2024 · Gross 78% · Net 20% · Free cash 31% FY2025 · Gross 77% · Net 18% · Free cash 40%
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $608.8M net cash
  • Cash
  • Long-term debt
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Cash $228.6M · Long-term debt $194.2M FY2021 · Cash $234.3M · Long-term debt $190.0M FY2022 · Cash $243.8M · Long-term debt $189.6M FY2023 · Cash $311.7M · Long-term debt $178.6M FY2024 · Cash $453.0M · Long-term debt $163.0M FY2025 · Cash $752.5M · Long-term debt $143.7M
Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 57.73m +1.5% since FY2020
59.62m 56.77m FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · 56.89m FY2021 · 58.83m FY2022 · 59.62m FY2023 · 56.77m FY2024 · 57.14m FY2025 · 57.73m
  FY2020Dec 31, 2020 FY2021Dec 31, 2021 FY2022Dec 31, 2022 FY2023Dec 31, 2023 FY2024Dec 31, 2024 FY2025Dec 31, 2025
Revenue $159.7M $305.4M $437.9M $582.0M $714.7M $868.5M
Gross margin 83% 82% 81% 79% 78% 77%
Operating income $17.0M $87.5M $120.2M $192.0M $190.8M $208.5M
Net income -$36.9M $34.6M $181.5M $128.9M $145.5M $158.7M
Net margin -23% 11% 41% 22% 20% 18%
Earnings per share -$1.43 $0.58 $2.97 $2.13 $2.51 $2.71
Free cash flow -$3.0M $98.3M $144.3M $219.1M $218.7M $347.9M
Free cash margin -2% 32% 33% 38% 31% 40%
Cash $228.6M $234.3M $243.8M $311.7M $453.0M $752.5M
Long-term debt $194.2M $190.0M $189.6M $178.6M $163.0M $143.7M
Shareholders' equity $97.2M $186.5M $402.8M $467.0M $659.2M $870.2M
Shares outstanding 56.89m 58.83m 59.62m 56.77m 57.14m 57.73m

Filings

SEC EDGAR
FiledReportPeriod to Lag
Aug 4, 2026 Quarterly ↗ Jun 30, 2026 35d
May 7, 2026 Quarterly ↗ Mar 31, 2026 37d
Feb 24, 2026 Annual ↗ Dec 31, 2025 55d
Nov 4, 2025 Quarterly ↗ Sep 30, 2025 35d
Aug 5, 2025 Quarterly ↗ Jun 30, 2025 36d
May 6, 2025 Quarterly ↗ Mar 31, 2025 36d
Feb 25, 2025 Annual ↗ Dec 31, 2024 56d
Oct 29, 2024 Quarterly ↗ Sep 30, 2024 29d
Aug 6, 2024 Quarterly ↗ Jun 30, 2024 37d
Apr 30, 2024 Quarterly ↗ Mar 31, 2024 30d
Feb 22, 2024 Annual ↗ Dec 31, 2023 53d
Oct 31, 2023 Quarterly ↗ Sep 30, 2023 31d

Current reports

FiledDisclosed
Oct 13, 2026 Director or officer change · Regulation FD ↗
Aug 4, 2026 Results · Regulation FD ↗
Jul 16, 2026 Results · Director or officer change · Regulation FD ↗
May 14, 2026 Shareholder vote ↗
May 7, 2026 Results · Regulation FD ↗
Apr 14, 2026 Director or officer change · Regulation FD ↗
Apr 2, 2026 Director or officer change · Regulation FD ↗
Feb 24, 2026 Results · Regulation FD ↗
Jan 12, 2026 Results · Regulation FD ↗
Nov 4, 2025 Results · Regulation FD ↗
Oct 23, 2025 Results ↗
Sep 24, 2025 Regulation FD ↗